ESBATech esbatech.com


Public lists: Pharma Startups (4733)

ESBATech develops therapeutic single-chain fragment antibodies on the basis of its fully human antibody fragments for the treatment of various inflammatory diseases. The established know-how and expertise in antibody engineering is employed for the improvement and optimization of existing fragments for better stability and expression properties.

ESBATech develops therapeutic single-chain fragment antibodies on the basis of its fully human antibody fragments for the treatment of various inflammatory diseases. The established know-how and expertise in antibody engineering is employed for the i...Show all

Company (Acquired)

Phone:

Fax:

Wagistr. 21

8952
Switzerland

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
ESBATech $22M Sep 13, 2009
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related ESBATech Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 13 investors

Competitors

Company Status Description Investors

NeuroGenomeX

Madison, Wisconsin, United States
Alive / ActiveNeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in...Show allLogin to see details

GlycoFi

Lebanon, New Hampshire, United States
AcquiredGlycoFi, Inc. was founded in 2000 with the mission of dramatically improving the capacity and cost of producing human therapeutic proteins, while simultaneously enhancing their efficacy and safety as therapeutics. The company harnesses the inherent advantages of yeast and other fungal-based protein expression systems by engineering these systems to produce correctly glycosylated human therapeutic proteins, thus greatly increasing the efficiency, fidelity and scalability at which those proteins c...Show allLogin to see details
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Sequence based engineering and optimization of single chain antibodies Aug 23, 2012 Apr 10, 2018 Patent
Humanized immunobinders of cell-surface antigens Nov 20, 2015 Mar 06, 2018 Patent
Sequence based engineering and optimization of single chain antibodies Jun 25, 2008 Mar 06, 2018 Patent
Stable and soluble antibodies inhibiting vegf Jun 16, 2015 Jan 23, 2018 Patent
Protein sustained-release injectable formulation Aug 18, 2014 Jan 23, 2018 Patent
See all 53 patents